RxDoctor Payments DataLook up a doctor →

Frank Cotter, MD

Ophthalmology · Roanoke, VANPI 1932101037

Payments from drug & device makers

$874,198in general payments, 2019–2025

Across 582 payments — averaging $1502.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$435K
  • AbbVie$419K
  • Alcon Research LLC$16K
  • Alcon$2K
  • NEW World Medical,inc.$518
  • Ocular Therapeutix, Inc.$357
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$2,67918%
  • Travel & lodging$3,29022%
  • Food & beverage$9,06860%
  • Education$490%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$874,198 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$1,001,203
Medicare patients
1,829
Services billed
11,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost449$198,016
SimbrinzaBrinzolamide/Brimonidine Tart348$97,216
VyzultaLatanoprostene Bunod145$58,959
RhopressaNetarsudil Mesylate50$34,660
Dorzolamide Hcl1,867$29,715
Latanoprost4,062$28,245
Prednisolone Acetate943$26,606
Travoprost163$25,286
CombiganBrimonidine Tartrate/Timolol91$22,733
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol203$21,141
RestasisCyclosporine23$20,454
Brinzolamide84$19,302
Alphagan PBrimonidine Tartrate30$19,147
XiidraLifitegrast17$16,735
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat923$14,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$418,948$260,350593 claims
AlconSimbrinza, Azopt$2,069$101,242359 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$313$75,694162 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$128$47,71988 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm$145$19,30571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →